These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33877321)

  • 21. Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19.
    Lu L; Liu X; Jin R; Guan R; Lin R; Qu Z
    Biomed Res Int; 2020; 2020():7520746. PubMed ID: 33204713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 and diabetes: the contributions of hyperglycemia.
    Wang J; Meng W
    J Mol Cell Biol; 2020 Sep; 12(12):958-962. PubMed ID: 33002109
    [No Abstract]   [Full Text] [Related]  

  • 23. Age-Related Differences in Immunological Responses to SARS-CoV-2.
    Wong LSY; Loo EXL; Kang AYH; Lau HX; Tambyah PA; Tham EH
    J Allergy Clin Immunol Pract; 2020; 8(10):3251-3258. PubMed ID: 32861856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 25. The Fight Against Severe COVID-19: Can Parasitic Worms Contribute?
    Cai P; Mu Y; McManus DP
    Front Immunol; 2022; 13():849465. PubMed ID: 35222441
    [No Abstract]   [Full Text] [Related]  

  • 26. SARS 2 human coronavirus (COVID -19, SARS CoV2).
    McFee RB
    Dis Mon; 2020 Sep; 66(9):101063. PubMed ID: 32807536
    [No Abstract]   [Full Text] [Related]  

  • 27. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
    Sharma RK; Li J; Krishnan S; Richards EM; Raizada MK; Mohandas R
    Clin Sci (Lond); 2021 Jan; 135(1):1-17. PubMed ID: 33399851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
    Casucci G; Acanfora D; Incalzi RA
    Drugs Aging; 2020 Nov; 37(11):779-785. PubMed ID: 33084001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.
    Damiano S; Sozio C; La Rosa G; Santillo M
    Front Cell Infect Microbiol; 2020; 10():608435. PubMed ID: 33384971
    [No Abstract]   [Full Text] [Related]  

  • 30. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?
    Islam H; Chamberlain TC; Mui AL; Little JP
    Front Immunol; 2021; 12():677008. PubMed ID: 34234779
    [No Abstract]   [Full Text] [Related]  

  • 31. SARS-CoV-2, the autoimmune virus.
    Halpert G; Shoenfeld Y
    Autoimmun Rev; 2020 Dec; 19(12):102695. PubMed ID: 33130000
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases.
    Thankam FG; Agrawal DK
    J Thorac Cardiovasc Surg; 2021 Feb; 161(2):e217-e226. PubMed ID: 32631657
    [No Abstract]   [Full Text] [Related]  

  • 33. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
    Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
    Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.
    Naveed H; Elshafeey A; Al-Ali D; Janjua E; Nauman A; Kawas H; Kaul R; Saed Aldien A; Elshazly MB; Zakaria D
    J Clin Pharmacol; 2021 Aug; 61(8):987-1000. PubMed ID: 33635546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2.
    Ebrahimi SA
    Drug Dev Res; 2020 Nov; 81(7):765-767. PubMed ID: 32337769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
    de Maat S; de Mast Q; Danser AHJ; van de Veerdonk FL; Maas C
    Semin Thromb Hemost; 2020 Oct; 46(7):835-837. PubMed ID: 32526773
    [No Abstract]   [Full Text] [Related]  

  • 38. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones.
    Viveiros A; Rasmuson J; Vu J; Mulvagh SL; Yip CYY; Norris CM; Oudit GY
    Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H296-H304. PubMed ID: 33275517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.
    Meng X; Liu Y; Wei C; Zhang K; Zhang Y; Zhong M; Zhang C; Zhang Y
    Sci China Life Sci; 2021 May; 64(5):836-839. PubMed ID: 32975722
    [No Abstract]   [Full Text] [Related]  

  • 40. The Duplicitous Nature of ACE2 in COVID-19 Disease.
    Heyman SN; Kinaneh S; Abassi Z
    EBioMedicine; 2021 May; 67():103356. PubMed ID: 33910120
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.